Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age

Abstract Co-administration of oral live-attenuated human rotavirus vaccine RIX4414 ( Rotarix ™) and oral polio vaccine (OPV) was assessed. Healthy infants were randomised to receive 2-doses of either: RIX4414 or placebo co-administered with OPV (12 and 16 weeks of age); or RIX4414 or placebo given 1...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2009-02, Vol.27 (9), p.1333-1339
Main Authors: Zaman, K, Sack, D.A, Yunus, M, Arifeen, S.E, Podder, G, Azim, T, Luby, S, Breiman, R.F, Neuzil, K, Datta, S.K, Delem, A, Suryakiran, P.V, Bock, H.L
Format: Article
Language:English
Subjects:
Administration, Oral
Age
Allergy and Immunology
Antibodies, Viral - blood
Antibody Formation
Applied microbiology
Bangladesh - epidemiology
Biological and medical sciences
Children & youth
Confidence intervals
Developing countries
Diarrhea - epidemiology
Diarrhea - immunology
Diarrhea - virology
Double-Blind Method
Drug Administration Schedule
Female
Fundamental and applied biological sciences. Psychology
Gastroenteritis - epidemiology
Gastroenteritis - etiology
Gastroenteritis - immunology
Gastrointestinal disease
Human rotavirus
Humans
Immunization
Infant
LDCs
Male
Microbiology
Miscellaneous
Nutrition research
Oral poliovirus
Poliomyelitis - immunology
Poliovirus
Poliovirus Vaccines - administration & dosage
Poliovirus Vaccines - therapeutic use
Rotavirus
Rotavirus Infections - epidemiology
Rotavirus Infections - immunology
Rotavirus Vaccines - administration & dosage
Rotavirus Vaccines - therapeutic use
Vaccine
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Virology
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Co-administration of oral live-attenuated human rotavirus vaccine RIX4414 ( Rotarix ™) and oral polio vaccine (OPV) was assessed. Healthy infants were randomised to receive 2-doses of either: RIX4414 or placebo co-administered with OPV (12 and 16 weeks of age); or RIX4414 or placebo given 15 days after OPV. After vaccination, 56.5–66.7% of RIX4414 and 18.6% of placebo recipients had seroconverted for rotavirus IgA. No significant differences between RIX4414 groups with or without OPV co-administration were observed. No statistically significant differences were observed between groups for polio seroprotection rates. RIX4414 vaccine was immunogenic when co-administered with OPV and did not interfere with OPV seroprotection rates.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2008.12.059